Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kelly Chin (Dallas, United States of America), Kelly Chin, Richard Channick, Aryeh Fischer, Robert Frantz, Mardi Gomberg-Maitland, Leah Kleinman, Chad Miller, Elke Hunsche, Rohan Zamanian, David Badesch. Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan. Eur Respir J 2016; 48: Suppl. 60, 2394

Member's Comments

No comment yet.

Related content which might interest you: Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Responsiveness of cambridge pulmonary hypertension outcome review (CAMPHOR) scores and utility in pulmonary hypertension (PH) patients Source: Eur Respir J 2007; 30: Suppl. 51, 343s Year: 2007 Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Disease-targeted treatment improves cognitive function in patients with pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Pulmonary hypertension due to lung disease – Results from COMPERA Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Management of selexipag interruptions in the GRIPHON study Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Intravenous prostacyclin for pulmonary hypertension: Patient’s perspective on complications Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 A retrospective study of depressive illness in patients with pulmonary hypertension (PH) at a specialist centre Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different? Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016